News

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...
A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...
GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds Written by David Mills on June 20, 2025 — Fact checked by Jill Seladi-Schulman, Ph.D.